Here's What Key Metrics Tell Us About Clorox (CLX) Q2 Earnings

For the quarter ended December 2022, Clorox (CLX) reported revenue of $1.72 billion, up 1.4% over the same period last year. EPS came in at $0.98, compared to $0.66 in the year-ago quarter.The reported revenue represents a surprise of +2.96% over the Zacks Consensus Estimate of $1.67 billion. With the consensus EPS estimate being $0.65, the EPS surprise was +50.77%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Organic Sales Growth: 4% versus -0.63% estimated by four analysts on average.Net revenue-Health and Wellness: $635 million versus $639.89 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2% change.Net revenue-International [$M]: $286 million compared to the $280.71 million average estimate based on four analysts. The reported number represents a change of -3.4% year over year.Net revenue-Lifestyle [$M]: $332 million versus $322.43 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.Net revenue-Household [$M]: $462 million compared to the $399.72 million average estimate based on four analysts. The reported number represents a change of +9.2% year over year.View all Key Company Metrics for Clorox here>>>Shares of Clorox have returned +0.5% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2023In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023?From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don’t miss your chance to still be among the first to get in on these just-released stocks.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"